Physician profile
Sharon Seth
NPI 1922329465
$7,549.82
in general payments reported to CMS, 2019-2025
36 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $350 · 2021: $361 · 2022: $1,436 · 2023: $1,478 · 2024: $1,325 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.19 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,235.76 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $887.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $832.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $506.01 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $414.59 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $339.09 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $311.15 | 2019-2025 | |
| Pharming Healthcare, INC. | $283.74 | 2023-2025 | Ruconest |
| Incyte Corporation | $264.64 | 2022-2024 | Opzelura |
| Amgen INC. | $255.28 | 2021-2025 | Tezspire |
| Abbvie INC. | $206.95 | 2022-2024 | Rinvoq |
| Grifols USA, LLC | $187.86 | 2019-2024 | Xembify |
| Octapharma USA, INC. | $178.83 | 2022-2024 | Cutaquig |
| Csl Behring | $174.67 | 2019-2025 | Haegarda, Andembry |
| Kaleo, INC. | $158.19 | 2021-2024 | Auvi-Q |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $151.46 | 2019-2022 | |
| Alk-Abello, INC | $149.55 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Pfizer INC. | $135.13 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $106.37 | 2023-2025 | Orladeyo |
| Optinose US, INC. | $84.95 | 2020-2025 | |
| Mylan Specialty L.P. | $78.57 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $69.88 | 2022 | |
| Leo Pharma INC. | $68.47 | 2022-2023 | Adbry |
| Hikma Pharmaceuticals USA | $53.97 | 2023-2024 | Ryaltris |
| Shire North American Group INC | $48.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $48.22 | 2019 | |
| Organon LLC | $47.78 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $47.69 | 2025 | Neffy |
| Lilly USA, LLC | $47.37 | 2024-2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $39.29 | 2024 | Sajazir, Tascenso Odt |
| Azurity Pharmaceuticals, INC. | $35.90 | 2025 | Alvesco |
| Covis Pharma Gmbh | $27.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.38 | 2019 | |
| Ionis Pharmaceuticals, INC. | $22.27 | 2025 | Dawnzera |
| Phadia US INC. | $15.94 | 2022 | |
| Aytu Biopharma, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.